Skip to main content
SpringerLink
Log in

Drug Management of Psychiatric Co-morbidity in Multiple Sclerosis

  • Chapter
Neuropsychiatric Symptoms of Inflammatory Demyelinating Diseases

Part of the book series: Neuropsychiatric Symptoms of Neurological Disease ((NSND))

  • 971 Accesses

Abstract

Multiple sclerosis (MS) is associated with a higher risk of psychiatric comorbidities that have an impact on the evolution, prognosis, and quality of life of patients. Despite this observation, evidence-based data on the treatment of these psychiatric conditions are rather sparse. Selective serotonergic recapture inhibitors and serotonin norepinephrine reuptake inhibitors can be considered as the first-choice treatment for depression or anxiety disorder in MS patients. Second-generation antipsychotics are of interest in MS patients suffering of bipolar disorder, compared to lithium or anticonvulsants. They also have an efficacy on psychotic symptoms observed in MS patients. Adherence to treatment is also an important topic in these patients and needs to be evaluated and improved using psychoeducation programs. According to the consequences of psychiatric comorbidities, research on the efficacy of psychotropic drugs in MS patients must be developed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hogancamp WE, Rodriguez M, Weinshenker BG. The epidemiology of multiple sclerosis. Mayo Clin Proc. 1997;72:871–8.

    Article  CAS  PubMed  Google Scholar 

  2. Minden SL, Feinstein A, Kalb RC, Miller D, Mohr DC, Patten SB, et al. Guideline Development Subcommittee of the American Academy of Neurology. Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82(2):174–81.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Minden SL, Schiffer RB. Affective disorders in multiple sclerosis: review and recommendations for clinical research. Arch Neurol. 1990;47:98–104.

    Article  CAS  PubMed  Google Scholar 

  4. Sadovnick AD, Remick RA, Allen J, Swartz E, Yee IM, Eisen K, et al. Depression and multiple sclerosis. Neurology. 1996;46:628–32.

    Article  CAS  PubMed  Google Scholar 

  5. Minden SL, Orav J, Reich P. Depression in multiple sclerosis. Gen Hosp Psychiatry. 1987;9:426–34.

    Article  CAS  PubMed  Google Scholar 

  6. Joffe RT, Lippert GP, Gray TA, Sawa G, Horvath Z. Mood disorder and multiple sclerosis. Arch Neurol. 1987;44:376–8.

    Article  CAS  PubMed  Google Scholar 

  7. Schiffer RB, Caine ED, Bamford KA, Levy S. Depressive episodes in patients with multiple sclerosis. Am J Psychiatry. 1983;140:1498–500.

    Article  CAS  PubMed  Google Scholar 

  8. Patten SB, Beck CA, Williams JV, Barbui C, Metz LM. Major depression in multiple sclerosis: a population-based perspective. Neurology. 2003;61:1524–7.

    Article  CAS  PubMed  Google Scholar 

  9. Schiffer RB, Wineman NM, Weitkamp LR. Association between bipolar affective disorder and multiple sclerosis. Am J Psychiatry. 1986;143:94–5.

    Article  CAS  PubMed  Google Scholar 

  10. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld M, Petukhova M, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2007;64:543–52.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Korostil M, Feinstein A. Anxiety disorders and their clinical correlates in multiple sclerosis patients. Mult Scler. 2007;13:67–72.

    Article  CAS  PubMed  Google Scholar 

  12. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593–602.

    Article  PubMed  Google Scholar 

  13. Patten SB, Svenson LW, Metz LM. Psychotic disorders in MS: population-based evidence of an association. Neurology. 2005;65(7):1123–5.

    Article  PubMed  Google Scholar 

  14. Fragoso YD, Adoni T, Anacleto A, da Gama PD, Goncalves MV, Matta AP, et al. Recommendations on diagnosis and treatment of depression in patients with multiple sclerosis. Pract Neurol. 2014;14(4):206–9.

    Article  PubMed  Google Scholar 

  15. Schiffer RB, Wineman NM. Antidepressant pharmacotherapy of depression associated with multiple sclerosis. Am J Psychiatry. 1990;147:1493–7.

    Article  CAS  PubMed  Google Scholar 

  16. Mohr DC, Boudewyn AC, Goodkin DE, Bostrom A, Epstein L. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol. 2001;69:942–9.

    Article  CAS  PubMed  Google Scholar 

  17. Ehde DM, Kraft GH, Chwastiak L, Sullivan MD, Gibbons LE, Bombardier CH, et al. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis. Gen Hosp Psychiatry. 2008;30(1):40–8.

    Article  PubMed  Google Scholar 

  18. Ameis SH, Feinstein A. Treatment of neuropsychiatric conditions associated with multiple sclerosis. Expert Rev Neurother. 2006;6(10):1555–67.

    Article  CAS  PubMed  Google Scholar 

  19. Solaro C, Bergamaschi R, Rezzani C, Mueller M, Trabucco E, Bargiggia V, et al. Duloxetine is effective in treating depression in multiple sclerosis patients: an open-label multicenter study. Clin Neuropharmacol. 2013;36(4):114–6.

    Article  CAS  PubMed  Google Scholar 

  20. Ramasubbu R, Taylor VH, Samaan Z, Sockalingham S, Li M, Patten S, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditions. Ann Clin Psychiatry. 2012;24(1):91–109.

    PubMed  Google Scholar 

  21. Mattingly G, Baker K, Zorumski CF, Figiel GS. Multiple sclerosis and ECT: possible value of gadolinium-enhanced magnetic resonance scans for identifying high-risk patients. J Neuropsychiatry Clin Neurosci. 1992;4(2):145–51.

    Article  CAS  PubMed  Google Scholar 

  22. Goldman Consensus Group. The Goldman Consensus statement on depression in multiple sclerosis. Mult Scler. 2005;11(3):328–37.

    Article  Google Scholar 

  23. Carta MG, Moro MF, Lorefice L, Trincas G, Cocco E, Giudice ED, et al. The risk of bipolar disorders in multiple sclerosis. J Affect Disord. 2014;155:255–60.

    Article  CAS  PubMed  Google Scholar 

  24. Blanc F, Berna F, Fleury M, Lita L, Ruppert E, Ferriby D, et al. Inaugural psychotic events in multiple sclerosis? Rev Neurol (Paris). 2010;166(1):39–48.

    Article  CAS  Google Scholar 

  25. Sidhom Y, Ben Djebara M, Hizem Y, Abdelkefi I, Kacem I, Gargouri A, et al. Bipolar disorder and multiple sclerosis: a case series. Behav Neurol. 2014. doi:10.1155/2014/536503.

    PubMed Central  PubMed  Google Scholar 

  26. Kemp K, Lion JR, Magram G. Lithium in the treatment of a manic patient with multiple sclerosis: a case report. Dis Nerv Syst. 1977;38(3):210–1.

    CAS  PubMed  Google Scholar 

  27. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry. 2009;10(2):85–116. Erratum in: World J Biol Psychiatry. 2009;10(3):255.

    Article  PubMed  Google Scholar 

  28. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Möller HJ, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry. 2010;11(2):81–109.

    Article  PubMed  Google Scholar 

  29. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Möller HJ, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry. 2013;14(3):154–219.

    Article  PubMed  Google Scholar 

  30. Minden SL, Orav J, Schildkraut JJ. Hypomanic reactions to ACTH and prednisone treatment for multiple sclerosis. Neurology. 1988;38(10):1631–4.

    Article  CAS  PubMed  Google Scholar 

  31. Chwastiak LA, Ehde DM. Psychiatric issues in multiple sclerosis. Psychiatry Clin North Am. 2007;30(4):803–17.

    Article  Google Scholar 

  32. Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14 Suppl 1:S1.

    Article  PubMed Central  PubMed  Google Scholar 

  33. Pine DS, Douglas CJ, Charles E, Davies M, Kahn D. Patients with multiple sclerosis presenting to psychiatric hospitals. J Clin Psychiatry. 1995;56(7):297–306.

    CAS  PubMed  Google Scholar 

  34. Davids E, Hartwig U, Gastpar M. Antipsychotic treatment of psychosis associated with multiple sclerosis. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(4):743–4.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry B, CHU Clermont-Ferrand, University of Auvergne, EA 7280, 58 rue Montalembert, Clermont-Ferrand, 63000, France

    Pierre-Michel Llorca MD, Ph.D. & Ludovic Samalin MD

Authors
  1. Pierre-Michel Llorca MD, Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ludovic Samalin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pierre-Michel Llorca MD, Ph.D. .

Editor information

Editors and Affiliations

  1. Department of Neurology, Centre Hospitalier Universitaire Pellegrin, INSERM U 862, Université de Bordeaux, Bordeaux, Gironde, France

    Bruno Brochet

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Llorca, PM., Samalin, L. (2015). Drug Management of Psychiatric Co-morbidity in Multiple Sclerosis. In: Brochet, B. (eds) Neuropsychiatric Symptoms of Inflammatory Demyelinating Diseases. Neuropsychiatric Symptoms of Neurological Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-18464-7_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-18464-7_8

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-18463-0

  • Online ISBN: 978-3-319-18464-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation